GSK to acquire vaccine developer Affinivax in deal worth up to $3.3bn
GlaxoSmithKline (GSK) has agreed to acquire Affinivax, a Boston-based clinical-stage vaccine developer, in a deal worth up to $3.3 billion. The consideration includes an upfront payment of $2.1 billion and payments of up to $1.2 billion based on potential development milestones. Affinivax is engaged in developing vaccines by using its Multiple Antigen Presenting System (MAPS) […]